Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07843368
Recruiting Phase 1

Safety, Tolerability, PK, and PD of TGM-148 in Healthy Participants

NCT07843368 · tracked via the Priya Life Science UK tracker
Sponsor
Tangram Therapeutics Plc
Phase
Phase 1
Started
2026-10-16
Last updated
2026-10-22

Condition(s) studied

Healthy Participants

Investigational drug(s) / intervention(s)

TGM-148Placebo

TGM-148: TGM-148 is an investigational medicinal product administered by subcutaneous injection according to a protocol-defined regimen.

Placebo: Placebo administered by subcutaneous injection according to a protocol-defined regimen.

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-148 in healthy adults

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy adults aged 18 to 45 years who are able to provide written informed consent. * Medically suitable for study participation based on protocol-defined assessments. * Body mass index (BMI) between 18.0-30.0 kg/m² (inclusive) and a body weight \>50 kg. Exclusion Criteria: * Clinically significant medical conditions, laboratory abnormalities, or other findings that, in the opinion of the investigator, could increase risk, interfere with study participation, or confound interpretation of study results. * Recent participation in another investigational study. * Use of medications that are prohibited by the protocol. * Any other condition that would make the individual unsuitable for study participation as determined by the investigator.

Primary outcome measure(s)

  • Frequency and severity of adverse events [Safety and tolerability] — From start of study drug administration through 16 weeks after study drug administration.

Trial sites (1)

FacilityCityRegionStatus
Hammersmith Medicines Research London United Kingdom Recruiting

More Tangram Therapeutics Plc trials in the UK

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH Recruiting

Other trials for the same condition

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants Active, not recruiting
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 Starting soon
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections Recruiting
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) Active, not recruiting
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07843368 on ClinicalTrials.gov ↗ ← All trials in the UK